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Abstract
Introduction: The idiopathic inflammatory myopathies are rare diseases for which data regarding the natural
history, response to therapies and factors affecting mortality are needed. We performed this study to examine the
effects of treatment and clinical features on survival in polymyositis and dermatomyositis patients.
Methods: A total of 160 consecutive patients (77 with polymyositis and 83 with dermatomyositis) seen at the
University of Michigan from 1997 to 2003 were included. Medical records were abstracted for clinical, laboratory
and therapeutic data, including initial steroid regimen and immunosuppressive use. State vital records were utilized
to derive mortality and cause of death data. Survival was modeled by left-truncated Kaplan-Meier estimation and
Cox regression.
Results: The 5- and 10-year survival estimates were 77% (95% CI = 66 to 85), and 62% (95% CI = 48 to 73),
respectively, and the rates were similar for polymyositis and dermatomyositis. Survival between the sexes was
similar through 5 years and significantly lower thereafter for males (10-year survival: 18% male, 73% female; P =
0.002 for 5- to 10-year interval). The sex disparity was restricted to the polymyositis group. Increased age at
diagnosis and non-Caucasian race were associated with lower survival. Intravenous versus oral corticosteroid use
was associated with a higher risk of death among Caucasians (HR = 10.6, 95% CI = 2.1 to 52.8). Early survival
between patients treated with methotrexate versus azathioprine was similar, but survival at 10 years was higher for
the methotrexate-treated group (76% vs 52%, P = 0.046 for 5- to 10-year interval).
Conclusions: Patients treated initially with intravenous corticosteroids had higher mortality, which was likely
related to disease severity. Both methotrexate and azathioprine showed similar early survival benefits as first-line
immunosuppressive drugs. Survival was higher between 5 and 10 years in the methotrexate-treated group, but
could not be confirmed in multivariable modeling for the full follow-up period. Other important predictors of long-
term survival included younger age, female sex and Caucasian race.
Introduction
Polymyositis (PM) and dermatomyositis (DM) are idio-
pathic inflammatory myopathies (IIMs) characterized by
chronic muscle inflammation leading to progressive
symmetrical muscle weakness [1] and lung disease
which can include interstitial lung disease (ILD) [2],
respiratory muscle weakness and aspiration. A literature
review estimated PM and DM prevalence as 5.1 per
100,000 (1965 to 1995), with an overall female prepon-
derance (67%) [3]. A more recent review (1989 to 2008)
found no new estimates, underscoring the need for con-
temporary epidemiologic data [4].
PM and DM are associated with considerable morbidity
due to damage caused by both the disease and its treat-
ment, and 5-year survival estimates vary from 60% to
80% [5-8]. IIM patients self-report significantly poorer
health compared to the general population, and patients
with chronic, progressive disease experience significantly
greater pain. The therapeutic management of myositis is
challenging. Conventional approaches include baseline
measurements of muscle involvement followed by
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prednisone for 6 to 8 weeks [9]. Although corticosteroids
often remain the initial therapeutic choice, side effects
and limited efficacy require additional steroid-sparing
agents. The choice of agent largely depends on the
experience of the prescribing physician, and few data
exist to guide choice of drugs at initial treatment stages.
Comparative effectiveness research evaluates the bene-
fits and harms of different interventions, frequently in a
“real-world” setting. Immunosuppressive agents are
widely used in myositis as steroid-sparing agents, but
studies contrasting the long-term effectiveness of immu-
nosuppressive agents are lacking. We performed this
study to characterize mortality outcomes among IIM
patients and to evaluate predictors of mortality, includ-
ing demographics, clinical variables and treatment at
initial presentation.
Materials and methods
Patient population
A retrospective study was performed, including indivi-
duals meeting eligibility criteria, with in- or outpatient
visits at the University of Michigan between January
1997 and March 2003. Patients were identified based on
International Classification of Diseases, Ninth Revision,
Clinical Modification codes for PM or DM [10]. The
study population included prevalent and incident cases
with relevant codes, which were validated to meet prob-
able or definite Bohan and Peter criteria [11,12]. Patients
with inclusion body myositis (IBM) or overlap with
other connective tissue diseases were excluded. Medical
charts were reviewed for demographic, clinical and
laboratory data. Vital records for mortality and cause of
death data were obtained from the Michigan Depart-
ment of Community Health. This study was approved
by the University of Michigan Institutional Review
Board, with a waiver for informed consent.
Clinical data
Data collected included demographics, clinical charac-
teristics, medications, creatine kinase (CK) levels (as a
surrogate for disease activity), ILD (based on findings
consistent with ILD derived from pulmonary function
testing, chest X-ray or high-resolution computed tomo-
graphy), vital status and/or loss to follow-up with asso-
ciated dates. Treatment data included initial steroid
regimen categorized as none, intravenous corticosteroid
pulse treatment (IV pulse), high-dose oral prednisone (≥
60 mg/day) or lower-dose oral prednisone (< 60 mg/
daily). Immunosuppressive use, including methotrexate
(MTX) and azathioprine (AZA), was also documented.
Statistical analysis
The demographic characteristics between the PM and
DM groups were compared by two-sample t-tests,
Wilcoxon rank-sum tests or c2 tests. One-way analysis
of variance or Kruskal-Wallis tests were used to com-
pare continuous measures between more than two cate-
gories. Survival analysis was performed by the Kaplan-
Meier method using the left-truncated approach to
adjust for survival bias. Thus we estimated the probabil-
ity of survival as a function of time since diagnosis, with
risk of death restricted to the observation period (that
is, after January 1997). Follow-up time was calculated as
time from diagnosis until the first occurrence of one of
the following: death, loss to follow-up or censoring at
the end of the observation period (July 2003). The
equality of survival functions was calculated by logrank
test. Left-truncated univariate and multivariable Cox
proportional hazards regression were performed to esti-
mate hazard ratios. Data management and analysis were
performed using Stata software (StataCorp, College Sta-
tion, TX, USA).
Results
Patient characteristics
A total of 160 consecutive patients (77 PM and 83 DM)
comprised the study population. Characteristics of the
PM and DM patients are outlined in Table 1. Overall,
116 (72%) of the patients were female, and the patients’
mean age (± SD) at diagnosis was 48.4 ± 13.5 years.
Lifetime history of cancer was similar between PM and
DM patients, though the proportion of cancers diag-
nosed 3 years before or after diagnosis was significantly
higher in the DM group (11 of 12, 91.7%) than in the
PM group (5 of 13, 38.5%) (P = 0.01). Among patients
with a history of malignancy, the types of cancers in the
13 PM patients were 5 gynecologic, 3 breast, 2 lung, 2
skin and 1 lymphoma; in the 12 DM patients, the cancer
types were 3 gastrointestinal, 2 gynecologic, 2 breast, 2
skin, 2 lymphoma and 1 prostate.
Treatment
Data on the initial corticosteroid regimen was available
for 110 patients (20 IV pulse, 56 high-dose oral (≥ 60
mg/day), 27 < 60 mg/day oral and 7 no steroids). An
additional 50 patients were treated with steroids of
unknown dose. Treatment was administered in the inpa-
tient setting for 90% of patients on IV pulse corticoster-
oids, with 14% of patients receiving the high dose orally
and 0% of patients taking < 60 mg/day orally. CK levels
were available within 3 months of PM and DM diagno-
sis in 73 of the 153 patients who were treated with cor-
ticosteroids. CK levels (in IU/L) tended to be highest in
the IV pulse group (median = 2,905, IQR = 681 to
11,062), followed by high-dose oral (median = 2,216,
IQR = 300 to 6,488) then lower-dose oral (median =
791, IQR = 30 to 4,000), though these levels were not
significantly different.
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Immunosuppressive drugs were used in 147 (92%) of
the patients, with the largest proportion being MTX (n
= 75, 47%) and AZA (n = 51, 32%). Other immunomo-
dulatory agents utilized were cyclophosphamide (6.3%),
cyclosporine (3.1%), mycophenolate mofetil (1.3%), TNF
blockers (0.6%) and intravenous immunoglobulin (1.9%).
Baseline characteristics, including diagnoses of PM and
DM, sex, race and age at diagnosis, were similar for
patients treated with MTX or AZA. Median CK levels
within 3 months of diagnosis in the 118 of 126 patients
for which we had available data who received either
MTX (median = 720, IQR = 109 to 2,600) or AZA
(median = 232, IQR = 83 to 1,766) did not reach a sta-
tistically significant difference.
Survival
The median follow-up was 4.6 years (IQR = 1.7 to 8.8).
The total time at risk in the analysis, corresponding to
the 160 patients, was 572.2 person-years. Overall 5- and
10-year survival for the study population were estimated
to be 77% (95% CI = 66 to 85) and 62% (95% CI = 48
to 73), respectively. Rates were not statistically different
between PM and DM, though they appeared higher for
PM (P = 0.12). Survival rates for PM were 87% (95% CI
= 69 to 95) at 5 years and 69% (95% CI = 49 to 83) at
10 years, and for DM the rates were 70% (95% CI = 53
to 82) at 5 years and 57% (95% CI = 34 to 74) at 10
years (Figure 1).
Although 5-year survival for the total PM and DM
population was similar between males (median = 73%,
95% CI = 48 to 88) and females (median = 78%, 95% CI
= 65 to 87) (P = 0.74), survival rates between the sexes
diverged thereafter (Figure 2). The 10-year survival
among males (median = 18%, 95% CI = 1 to 51) was
significantly lower than among females (median = 73%,
95% CI = 57 to 83) (logrank P = 0.002 corresponding to
the 5- to 10-year analysis time interval). Significance
testing was not appropriate over the full follow-up per-
iod because of lack of conformity with the proportional
hazards assumption. Further inspection utilizing Cox
modeling (Table 2) revealed a significant interaction
between sex and PM and DM diagnoses, with the dis-
parity in survival by sex detected only in the PM group.
Kaplan-Meier estimates adjusted for sex were similar for
the PM and DM groups (data not shown), with sex-
adjusted 5-year survival rates of 62% and 65%, respec-
tively (P = 0.31). Kaplan-Meier estimates according to
initial corticosteroid regimen indicated higher mortality
for the IV versus oral group (P = 0.0002) (Figure 3).
Five-year survival estimates were 91% (95% CI = 77 to
97) and 54% (95% CI = 25 to 76) for the oral and IV
groups, respectively. When the oral corticosteroid group
by was stratified dose, survival was similar between
patients receiving < 60 versus ≥ 60 mg/day (data not
shown). Estimates comparing survival according to type
of immunosuppressive revealed similar 5-year survival
for patients treated with MTX (80%, 95% CI = 64 to 89)
versus AZA (78%, 95% CI = 49 to 91) (Figure 4). From
5 years onward, however, survival was higher in the
MTX group. The 10-year survival was 76% for MTX
(95% CI = 60 to 87) and 52% for AZA (95% CI = 28 to
72) (P = 0.046 for the 5- to 10-year interval).
On the basis of univariate Cox regression, age at diag-
nosis was significantly associated with survival (HR =
1.06, 95% CI = 1.02 to 1.09; P = 0.001), indicating that
each year of increase in age at diagnosis was associated
with a 6% increase in the hazard ratio of death. Race
was likewise associated with survival (HR = 1.7, 95% CI
= 1.05 to 2.82 for non-Caucasians versus Caucasians).
The first CK level and ILD were not associated with
Table 1 Demographics and baseline characteristics of patients with PM versus DMa
Characteristics PM (n = 77) DM (n = 83) P value
Age at diagnosis (years) 49.7 ± 13.0 47.2 ± 13.9 0.236
Females, n (%) 60 (77.9) 56 (67.5) 0.139
Race, n (%) 0.042
White, non-Hispanic 61 (79.2) 52 (62.7)
Black 13 (16.9) 15 (18.1)
Hispanic 0 (0) 2 (2.4)
Asian 0 (0) 1 (1.2)
Other or unknown 3 (3.9) 13 (15.7)
Median [IQR] initial CK level (IU/L)b 3,250 [846 to 11,698] 415 [71 to 3,000] 0.0005
Interstitial lung disease, n (%) 21 (27.3) 16 (19.3) 0.231
Cancer, n (%)
Ever 13 (16.9) 12 (14.5) 0.673
Proportion diagnosed within ± 3 years of IIM diagnosis 5 (38.5) 11 (91.7) 0.01
aCK = creatine kinase; DM = dermatomyositis; IIM = idiopathic inflammatory myopathy; PM = polymyositis. bIncludes CK values (if available) within 3 months of
IIM diagnosis. Results are expressed as means ± SD or number (%).
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survival (HR = 1.0, 95% CI = 1.0 to 1.0, and HR = 0.7,
95% CI = 0.3 to 1.9), respectively.
Multivariable Cox analysis regression was performed
to further explore the above-described associations
(Table 2). When medication use was excluded, statisti-
cally significant associations were found for sex, age at
diagnosis, race and interaction between sex and PM
and DM diagnoses. When immunosuppressive use was
additionally modeled, the results were similar to the
model without medication use. Because of nonconfor-
mance with the proportional hazards assumption
shown in Figure 4, the results from the Cox regression
models incorporating immunosuppressive drug type
have limited utility. In the multivariable model includ-
ing steroid use, a statistically significant increase in the
HR of death persisted for IV versus oral delivery (HR
= 5.6; 95% CI = 1.6 to 20.3). Moreover, estimates for
race and the interaction between sex and diagnosis
were no longer significant when adjusting for steroid
use, and the significance level for the main effect of
sex was reduced to borderline. Separate models were
consequently fit according to race and revealed that IV
versus oral steroid treatment persisted only as a signifi-
cant predictor for Caucasians, among whom the mag-
nitude of association also became stronger (HR = 10.6,
95% CI = 2.1 to 52.8 Caucasians; HR = 1.3, 95% CI =
0.2 to 11.7 African Americans).
When steroid and immunosuppressive use were
simultaneously included in the multivariable model, the
results were similar to the multivariable model with
steroid but not immunosuppressive use (data not
shown). No appreciable differences in effect estimates
were found CK level or ILD was added to the models
(data not shown). Cancer (defined as either ever or
within 3 years of IIM diagnosis) likewise was not
included in the final models, because it was not signifi-
cantly associated with survival and did not materially
affect the estimates of other covariates in the models
(data not shown).
Causes of death among the 27 patients who died dur-
ing the follow-up period were cardiac in 22% (4 acute
myocardial infarction and 2 congestive heart failure),
respiratory in 22% (2 interstitial lung disease, 2 acute
respiratory distress syndrome, 1 respiratory failure and 1
asthma), infection in 15% (2 sepsis and 2 pneumonia),
cancer in 11% (1 lung, 1 sarcoma and 1 esophageal) and
other causes in 30% (1 renal failure, 1 multiorgan fail-
ure, 1 brain hemorrhage, 1 intestinal ischemia/bowel
infarction, 1 dermatomyositis, 1 traumatic injury and 2
unknown).
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Figure 1 Kaplan-Meier estimates for survival in polymyositis (PM) and dermatomyositis (DM) patients. Each tick mark corresponds to a
time of patient censoring. Survival rates were not significantly different according to diagnosis (P = 0.12).
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Discussion
The effect of treatment on outcomes of complex diseases
such as PM and DM is challenging to study because of
factors that include the rarity of these disorders, the het-
erogeneity of clinical phenotypes and the lack of sensitive
outcome measures. There are no large-scale, randomized
controlled trials of IIM confirming the efficacy of com-
monly recommended immunosuppressive drugs. In our
study, we evaluated a relatively large cohort of 160
patients and offer a unique perspective on prognostic fac-
tors for patients with PM and DM.
Overall 5-year survival in our cohort was 77%, which
is consistent with prior estimates of 60% to 80% [5-8],
though a small British study reported 95% [13]. Of the
27 deaths, cardiovascular and respiratory disease were
the leading causes (22% each), followed by infections
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Figure 2 Kaplan-Meier estimates comparing survival in patients with idiopathic inflammatory myopathy (polymyositis and
dermatomyositis) by sex. Each tick mark corresponds to a time of patient censoring. The sex disparity was most pronounced among the
polymyositis subset (see text “Survival” section).
Table 2 Results derived from multivariable Cox regression modelsa
Model A: No medications included Model B: Corticosteroid included Model C: AZA/MTX included
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Sex (male referent) 0.14 (0.04 to 0.58) 0.006 0.10 (0.01 to 1.27) 0.076 0.09 (0.02 to 0.52) 0.007
Age at diagnosis (years) 1.07 (1.04 to 1.11) 0.000 1.06 (1.01 to 1.12) 0.018 1.11 (1.06 to 1.16) 0.000
Race (white referent)
Black 3.94 (1.48 to 10.46) 0.006 1.5 (0.3 to 7.4) 0.61 9.5 (2.42 to 37.09) 0.001
Other or unknown 2.03 (0.66 to 6.29) 0.22 0.86 (0.19 to 4.0) 0.85 5.6 (1.3 to 24.3) 0.021
Diagnosis (PM referent) 0.78 (0.24 to 2.54) 0.681 1.14 (0.26 to 5.1) 0.86 0.30 (0.1 to 1.5) 0.141
Sex-diagnosis interaction 6.41 (1.22 to 33.7) 0.028 12.5 (0.65 to 241.5) 0.10 15.7 (1.9 to 128.0) 0.010
IV corticosteroid (vs oral) - - 5.6 (1.6 to 20.3)b 0.008 - -
MTX (vs AZA) - - - - 0.96 (0.3 to 2.8) 0.938
aAZA = azathioprine; CK = creatine kinase; IIM = idiopathic inflammatory myopathy; ILD = interstitial lung disease; IV = intravenous; MTX = methotrexate; PM =
polymyositis. bSteroid association was restricted to the white subset of the study population when stratified models were used. Inclusion of initial CK level,
comorbid ILD or cancer (ever or within 3 years of IIM diagnosis) in additional models did not substantively affect results.
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and cancer. Autoimmune disorders, such as lupus, are
recognized to increase risk of cardiovascular disease,
which is not explained by traditional risk factors [14]
but by rather adverse effects of cumulative steroid expo-
sure and proposed mechanisms such as endothelial cell
apoptosis [15] and increased IFN-a expression [16]. As
reviewed by Lundberg and Forbess [17], cardiovascular
disease, infection and cancer have been observed to be
the leading three causes of death in other myositis stu-
dies. The high ranking of respiratory disease as a cause
of death in our study could in part be a reflection of
our center’s serving as a tertiary care referral center for
ILD, which could factor into the number or severity of
patients with these concomitant diagnoses.
We evaluated whether the initial steroid regimen had
an impact on survival and found that patients treated
initially with IV corticosteroids had higher mortality
that was likely related to disease severity. Of patients
receiving pulses of IV steroids, 90% were hospitalized,
which may indicate greater perceived disease severity
warranting inpatient management. Other factors, such
as comorbidities, poor functional status at baseline and
complications of high-dose steroid use, could also con-
tribute to an ostensible increase in mortality associated
with IV steroid use. Only seven patients (4%) were
treated without steroids. We categorized initial steroid
exposure as either high to low or moderate dose, and by
route, because mechanisms of action may vary accord-
ingly. The molecular mechanisms of glucocorticoids are
complex and involve at least four pathways, which were
reviewed by Buttgereit et al. [18]: the classic genomic
action through activation of the cytosolic glucocorticoid
receptor (cGR), a secondary nongenomic action initiated
by the cGR, a membrane-bound glucocorticoid receptor
(mGR)-mediated nongenomic action and nonspecific,
nongenomic actions involving cell membranes. High
concentrations of glucocorticoids likely cause the non-
specific nongenomic immunosuppressive and anti-
inflammatory effects by permeating plasma and mito-
chondrial membranes and are thought to underlie the
rapid effects associated with IV pulse therapy [19].
Though steroids are widely used for the treatment of
IIM, the role of corticosteroid dose has not been for-
mally assessed in a large prospective cohort. A retro-
spective analysis showed that patients treated with high
doses of prednisone displayed improved muscle strength
and earlier recovery of function [20]. Another retrospec-
tive study found that high-dose prednisone regimens
offered no survival benefit over low-dose regimens in
patients with PM [21].
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Figure 3 Kaplan-Meier estimates comparing survival among idiopathic inflammatory myopathy patients according to initial
corticosteroid regimen of intravenous (IV) versus oral. Each tick mark corresponds to a time of patient censoring.
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In our study, the finding of increased mortality in
association with IV versus oral steroids was observed
among Caucasians, though not among other racial
groups. It is unclear why this association was restricted
to Caucasians, but varying immunogenetic profiles exist
among IIM patients from different racial and ethnic
groups and such disease heterogeneity could lead to dif-
ferential treatment responses [22]. Alternatively, poten-
tial differences in prescribing patterns between races
could bias results. In our population, 41% of African
Americans and 15% of Caucasians received IV corticos-
teroids (P = 0.046). Unfortunately, we are unable to
tease apart the factors underlying the choice of corticos-
teroid regimen. The proportion of patients with comor-
bid ILD was not statistically different between
Caucasians (21%) and African Americans (36%), whereas
CK levels were higher among African Americans (med-
ian = 1,256, IQR = 257 to 7,727) compared with Cauca-
sians (median = 333, IQR = 94 to 1998) (P = 0.02).
Retrospective categorization of disease severity is proble-
matic for inflammatory myopathies because of inconsis-
tencies in muscle-strength assessment and other
nonstandard measures of disease activity.
In our study, we compared the two most commonly
prescribed immunosuppressive medications, AZA and
MTX, both of which are used widely for the treatment
of autoimmune diseases as steroid-sparing agents. An
open-label trial of 22 patients with refractory disease
showed that placing patients on MTX reduced the daily
prednisone dose at 6 months [23]. In a randomized con-
trolled trial designed to assess the effect of AZA in com-
bination with prednisone versus prednisone alone, 16
patients with PM were studied. There was no significant
difference between the two groups after 3 months [24],
but the 3-year follow-up showed an improvement in
function and a decrease in daily prednisone dosage [25].
MTX and AZA have been compared in only one dou-
ble-blinded randomized controlled trial of 28 patients
with PM and DM [26]. Handheld myometry was the
primary end point, which is a measure of grip strength
that has not been validated for patients with inflamma-
tory myopathies, and testing of proximal muscle groups
may be more sensitive to change. The hand-grip
strength after 1 year was similar between MTX and
AZA groups, although MTX was better tolerated.
In our study, as depicted in the unadjusted Kaplan-
Meier curves, 5-year survival was similar among patients
treated with MTX and those treated with AZA, whereas
survival was higher in the MTX group from 5 years
onward. In the Cox model, adjusting for various
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Figure 4 Kaplan-Meier survival estimates, according to azathioprine versus methotrexate use. Each tick mark corresponds to a time of
patient censoring.
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demographic and clinical factors, a difference in the
hazard ratio of mortality according to type of immuno-
suppressive was not detected, though because of the
lack of conformity with the proportional hazards
assumption, these results must be interpreted with cau-
tion. Our results are compatible with those from a
cohort of 113 patients (PM, DM and IBM) suggesting
superiority of MTX versus AZA in terms of complete
and partial clinical responses (subjectively defined)
among men, as well as anti-synthetase antibody-positive
subsets [27]. In our study population, baseline character-
istics were similar among patients treated with MTX
versus AZA, including CK levels and ILD, which are
potential indicators of disease severity. In fact, though
not reaching a statistically significant difference, CK
levels were higher in the MTX group. Although the pre-
sence of lung disease could influence the selection of
immunosuppressive agents, with AZA potentially being
chosen for ILD patients to avoid MTX-associated lung
injury, we were not able to retrospectively confirm a
rationale for choice of drug. However, the proportion of
ILD patients treated with AZA (26%) was similar to
those who were given MTX (21%) (P = 0.586). In this
PM and DM population, we also did not find an asso-
ciation between comorbid ILD and survival.
Several studies have suggested that higher CK levels
are associated with increased disease activity [11,13,28],
though levels are not always reliable as predictors of dis-
ease activity or therapeutic response, despite their being
used widely in clinical practice. A higher initial CK level
may be associated with a more rapidly progressing
course, prompting patients to seek treatment more
quickly. In this cohort, initial CK was not associated
with survival. Similarly, though the initial CK level was
significantly higher for PM than for DM, there was no
significant difference in survival between these groups.
The higher CK levels in the IV pulse treatment group
did not reach statistical significance compared with the
other two treatment groups.
In our study, we found a female-to-male ratio consis-
tent with other studies. Ten-year survival was signifi-
cantly lower among males versus females, with the
disparity being most evident in the PM group. These
data are consistent with accumulating data from studies
of other autoimmune diseases, such as lupus, suggesting
greater severity among men despite higher incidence
among women [29]. As reviewed elsewhere, however,
the results from prior myositis studies are inconsistent
with respect to whether male sex is associated with
reduced survival [17].
Several limitations of the present study should be con-
sidered, including its retrospective nature and conduct
at a single center. Though it would be interesting to
assess survival from disease onset and the potential
impact of delay until diagnosis, we were unable to do so
because of the difficulty in reliably ascertaining dates of
IIM onset. Detailed autoantibody profiles were likewise
not uniformly available, though such data would be of
prognostic interest. Our center is a tertiary care facility,
and it is possible that our cohort could have had greater
disease severity due to referral bias. Although IV pulse
steroid treatment was found to be associated with high
mortality in this population, it is likely that this observa-
tion is due to confounding by indication whereby
patients may have received this treatment because of
more severe disease. We could not determine the rea-
sons underlying the choice of immunosuppressive regi-
men, but the apparent difference in long-term survival
favoring MTX may be attributable to confounding fac-
tors and therefore may not represent a true difference
between the two treatment groups.
Conclusions
In summary, we have identified variables associated with
survival in a large cohort of patients with PM and DM.
We were specifically interested in determining the com-
parative effectiveness of different regimens of corticos-
teroids and immunosuppressive drugs. We could not
identify improved survival associated with the use of
pulsed IV corticosteroids, and, in fact, survival was
lower, which was likely related to disease severity. Survi-
val at 5 years was similar for patients treated with MTX
and AZA, and the observed higher survival associated
with MTX after 5 years could not be confirmed in mul-
tivariable modeling for the full follow-up period. Our
data underscore the importance of evaluating long-term
outcomes in the real-world setting, and prospective,
multicenter studies should be conducted to further
explore these findings.
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